Over the last decade, the use of stereotactic radiosurgery (SRS) for the treatment of intracranial lesions has grown significantly. In addition to malignant brain tumors and vascular malformations, benign tumors have also been treated with SRS. Although surgical resection has long been considered the gold standard in the management of such benign lesions, the outcomes of SRS in various benign neoplasms appears to be comparable. In this review, we will examine the literature as it pertains to the treatment of benign brain tumors with SRS. Of particular note, we will examine the results of SRS in acoustic neuromas, meningiomas, pituitary adenomas, and other benign tumors.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1177/153303460300200208 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Impact of MLC error on dose distribution in SRS treatment of single-isocenter multiple brain metastases: comparison between DCAT and VMAT techniques.
Rep Pract Oncol Radiother
December 2024
Department of Radiation Oncology, Kagawa University Hospital, Kagawa, Japan.
Background: Dynamic conformal arc therapy (DCAT) and volumetric modulated arc therapy (VMAT) can achieve near equal plan quality in single-isocenter multiple target stereotactic radiosurgery (SRS) for brain metastases. This study aimed to investigate the impact of multi-leaf collimator (MLC) errors during beam delivery on the dose distribution for each technique.
Materials And Methods: A 10-mm diameter delineation of the three targets was employed on the computed tomography images of a head phantom, and the reference plans were created using the DCAT and VMAT.
Acromegaly: diagnostic challenges and individualized treatment.
Expert Rev Endocrinol Metab
January 2025
Department of Medicine, Vagelos College of Physicians & Surgeons, Columbia University, New York, NY, USA.
Introduction: Acromegaly is due in almost all cases to a GH-secreting pituitary tumor. GH and IGF-1 excesses lead to its multi-system clinical manifestations and comorbidities. Acromegaly is under-diagnosed and typically presents with advanced disease.
View Article and Find Full Text PDFBrain radiotherapy combined with camrelizumab and platinum-doublet chemotherapy for previously untreated advanced non-small-cell lung cancer with brain metastases (C-Brain): a multicentre, single-arm, phase 2 trial.
Lancet Oncol
January 2025
Department of Thoracic Medical Oncology, Zhejiang Cancer Hospital, Hangzhou Institute of Medicine, Chinese Academy of Sciences, Hangzhou, China. Electronic address:
Background: Brain metastases are a common complication in patients with non-small-cell lung cancer (NSCLC) lacking actionable driver mutations, with limited treatment options and poor prognosis. We aimed to investigate the efficacy and safety of brain radiotherapy combined with camrelizumab and platinum-doublet chemotherapy in patients with newly diagnosed advanced NSCLC and brain metastases.
Methods: This multicentre, single-arm, phase 2 trial was done across nine tertiary hospitals in China.
Outcomes of Stereotactic Body Radiation Therapy for Large Uveal Melanoma: A Retrospective Analysis of Asian Population.
Cancer Res Treat
December 2024
Department of Radiation Oncology, Yonsei Cancer Center, Heavy Ion Therapy Research Institute, Yonsei University College of Medicine, Seoul.
Purpose: To investigate the clinical outcomes of stereotactic body radiation therapy (SBRT) in patients with large uveal melanoma (UM).
Materials And Methods: We conducted a retrospective review of 64 consecutive patients with UM treated with Cyberknife at Yonsei Cancer Center from September 2015 to October 2021. The median radiation dose was 60 Gy (range 48-64 Gy) administered in four fractions every alternate day.
Early outcomes following local salvage treatment with MRI-assisted low-dose rate brachytherapy (MARS) for MRI-visible postsurgical bed recurrences and focal intraprostatic recurrences.
Brachytherapy
January 2025
Department of Genitourinary Radiation Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX.
Background: To determine outcomes of MRI-assisted radiosurgery (MARS) for salvage brachytherapy using the radioisotope Pd after various upfront treatments including surgery, external beam radiotherapy, and brachytherapy.
Methods: We retrospectively reviewed data for patients who underwent salvage MARS for intraprostatic lesions or prostate bed recurrences from 2016 to 2022. Biochemical recurrence, prostate cancer-specific, and overall survival, and the cumulative incidences of toxicities, were determined by Kaplan-Meier estimates.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!